公开(公告)号：US20170291934A1

公开(公告)日：2017-10-12

申请号：US15511956

申请日：2015-09-21

申请人： Charles C. REED ,  Gregory Ian FROST ,  Joan Mazzarelli SOPCZYNSKI ,  Chi ZHANG ,  INTREXON CORPORATION

发明人： CHARLES C. REED ,  GREGORY IAN FROST ,  JOAN MAZZARELLI SOPCZYNSKI ,  CHI ZHANG

IPC分类号： C07K14/54 ,  G01N33/567 ,  G01N33/50 ,  A61K45/00 ,  C12P21/02

CPC分类号： C07K14/5434 ,  A61K38/00 ,  A61K45/05 ,  C07K14/54 ,  C12P21/02 ,  G01N33/50 ,  G01N33/567

摘要： The present invention relates to modified forms of IL-12. These modified forms of IL-12 may be engineered to have a shortened in vivo half-life compared and/or enhanced localization of biological effects compared to that of corresponding non-modified form of IL-12. Short half-life and membrane bound forms of IL-12 may provide greater therapeutic control for in vivo therapeutic delivery, in particular when used in combination with ligand inducible delivery of IL-12. Modified forms of IL-12 engineered to have shortened in vivo half-life and/or enhanced localization of biological effects include heterodimeric p35/p40, single chain and membrane bound forms of IL-12 wherein a naturally occurring IL-12 amino acid sequence is genetically modified to enhance susceptibility of the IL-12 molecule to in vivo proteolytic degradation.

公开(公告)号：US09333244B2

公开(公告)日：2016-05-10

申请号：US13815311

申请日：2013-02-19

申请人： Xiaoming Li ,  Mysore Ramprasad ,  Curtis Thompson ,  Harold Michael Shepard ,  Louis Howard Bookbinder ,  Gregory Ian Frost

发明人： Xiaoming Li ,  Mysore Ramprasad ,  Curtis Thompson ,  Harold Michael Shepard ,  Louis Howard Bookbinder ,  Gregory Ian Frost

IPC分类号： A61K38/00 ,  A61K38/47 ,  A61K9/00 ,  A61K9/127

CPC分类号： A61K38/47 ,  A61K9/0034 ,  A61K9/127

摘要： Provided are compositions and formulations or co-formulations containing a hyaluronan degrading enzyme. The compositions, formulations or co-formulations can also contain another therapeutic agent, such as one that is suitable for treatment of Benign Prostatic Hyperplasia, for example, a 5-alpha reductase inhibitor. The compositions and formulations can be used for the treatment of Benign Prostatic Hyperplasia. The compositions and formulations can be provided in combinations with one or more other agents for the treatment of Benign Prostatic Hyperplasia.

公开(公告)号：US20130251786A1

公开(公告)日：2013-09-26

申请号：US13815311

申请日：2013-02-19

申请人： Xiaoming Li ,  Mysore Ramprasad ,  Curtis Thompson ,  Harold Michael Shepard ,  Louis Howard Bookbinder ,  Gregory Ian Frost

发明人： Xiaoming Li ,  Mysore Ramprasad ,  Curtis Thompson ,  Harold Michael Shepard ,  Louis Howard Bookbinder ,  Gregory Ian Frost

IPC分类号： A61K38/47

CPC分类号： A61K38/47 ,  A61K9/0034 ,  A61K9/127

摘要： Provided are compositions and formulations or co-formulations containing a hyaluronan degrading enzyme. The compositions, formulations or co-formulations can also contain another therapeutic agent, such as one that is suitable for treatment of Benign Prostatic Hyperplasia, for example, a 5-alpha reductase inhibitor. The compositions and formulations can be used for the treatment of Benign Prostatic Hyperplasia. The compositions and formulations can be provided in combinations with one or more other agents for the treatment of Benign Prostatic Hyperplasia.

摘要翻译： 提供含有透明质酸降解酶的组合物和制剂或共同制剂。 组合物，制剂或配制剂还可以含有另一种治疗剂，例如适用于治疗良性前列腺增生的治疗剂，例如5-α还原酶抑制剂。 组合物和制剂可用于治疗良性前列腺增生。 组合物和制剂可以与一种或多种其它药物组合提供，用于治疗良性前列腺增生。